<SEC-DOCUMENT>0001193125-17-368814.txt : 20171214
<SEC-HEADER>0001193125-17-368814.hdr.sgml : 20171214
<ACCEPTANCE-DATETIME>20171214073956
ACCESSION NUMBER:		0001193125-17-368814
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171214
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171214
DATE AS OF CHANGE:		20171214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUMANA INC
		CENTRAL INDEX KEY:			0000049071
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				610647538
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05975
		FILM NUMBER:		171255154

	BUSINESS ADDRESS:	
		STREET 1:		500 W MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202
		BUSINESS PHONE:		5025801000

	MAIL ADDRESS:	
		STREET 1:		500 W. MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXTENDICARE INC
		DATE OF NAME CHANGE:	19740404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HERITAGE HOUSE OF AMERICA INC
		DATE OF NAME CHANGE:	19671129
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d464609d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(D) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): December&nbsp;14, 2017 (December 14, 2017) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Humana Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name
of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of Incorporation) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">1-5975</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">61-0647538</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>500 West Main Street, Louisville, KY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>40202</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip&nbsp;Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">502-580-1000</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act
<FONT STYLE="white-space:nowrap">(17&nbsp;CFR&nbsp;240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act
<FONT STYLE="white-space:nowrap">(17&nbsp;CFR&nbsp;240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934
<FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc. issued a press release this morning, a copy of which is attached hereto as
Exhibit 99.1, and which is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d464609dex991.htm">Press Release. </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HUMANA INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>BY:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cynthia H. Zipperle</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cynthia H. Zipperle</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Chief Accounting Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and
Controller</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Accounting Officer)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:&nbsp;December 14, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d464609dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>n&nbsp;e&nbsp;w&nbsp;s</B>&nbsp;r&nbsp;e&nbsp;l&nbsp;e&nbsp;a&nbsp;s&nbsp;e</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500&nbsp;West&nbsp;Main&nbsp;Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box 1438</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Louisville, KY 40202</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>http://www.humana.com</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION CONTACT:</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amy Smith</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Humana Investor Relations</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(502) <FONT STYLE="white-space:nowrap">580-2811</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">e-mail:</FONT> Amysmith@humana.com</U></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tom Noland</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Humana Corporate Communications</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(502) <FONT STYLE="white-space:nowrap">580-3674</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">e-mail:</FONT> Tnoland@humana.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g464609img001.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Humana Announces $3 Billion Share Repurchase Authorization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Louisville, KY</B> &#150; December&nbsp;14, 2017 &#150; Humana Inc. (NYSE: HUM) announced today that its Board of Directors has approved a $3&nbsp;billion
share repurchase authorization with an expiration date of December&nbsp;31, 2020, replacing its previous $2.25&nbsp;billion share repurchase authorization, which has no further capacity. The company may repurchase shares from time to time at
prevailing prices in the open market, by block purchases or in privately-negotiated transactions (including pursuant to an accelerated share repurchase agreement with an investment bank). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Cautionary Statement </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release includes
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the
approval of one of Humana&#146;s executive officers, the words or phrases like &#147;expects,&#148; &#147;believes,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;likely will result,&#148; &#147;estimates,&#148; &#147;projects&#148; or
variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including,
among other things, information set forth in the &#147;Risk Factors&#148; section of the company&#146;s SEC filings, a summary of which includes but is not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable
to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana&#146;s profitability
could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment
patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current
and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates, however, involve extensive judgment, and have considerable inherent variability because they are extremely
sensitive to changes in claim payment patterns and medical cost trends, so any reserves the company may establish, including premium deficiency reserves, may be insufficient. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Humana fails to effectively implement its operational and strategic initiatives, particularly its Medicare
initiatives, state-based contract strategy, and its participation in the new health insurance exchanges, the </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
company&#146;s business may be materially adversely affected, which is of particular importance given the concentration of the company&#146;s revenues in these products. In addition, there can be
no assurances that the company will be successful in maintaining or improving its Star quality ratings in future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The divestiture of Humana&#146;s subsidiary, KMG America Corporation, is subject to various closing conditions, including various regulatory approvals and customary closing conditions, as well as other uncertainties,
and there can be no assurances as to whether and when it may be completed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If Humana fails to properly maintain the integrity of its data, to strategically implement new information systems, to protect Humana&#146;s proprietary rights to its systems, or to defend against cyber-security
attacks, the company&#146;s business may be materially adversely affected. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes relating to rate adjustments resulting from the Balanced Budget and
Emergency Deficit Control Act of 1985, as amended, commonly referred to as &#147;sequestration&#148;; other provider contract disputes; and qui tam litigation brought by individuals on behalf of the government) and governmental and internal
investigations, any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company&#146;s cost of doing
business. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss
of material government contracts, governmental audits and investigations, potential inadequacy of government determined payment rates, potential restrictions on profitability, including by comparison of profitability of the company&#146;s Medicare
Advantage business to <FONT STYLE="white-space:nowrap">non-Medicare</FONT> Advantage business, or other changes in the governmental programs in which Humana participates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Healthcare Reform Law, including The Patient Protection and Affordable Care Act and The Healthcare and Education Reconciliation Act of 2010, could have a material adverse effect on Humana&#146;s results of
operations, including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company&#146;s ability to expand into new markets, increasing the company&#146;s medical and operating costs by, among
other things, requiring a minimum benefit ratio on insured products, lowering the company&#146;s Medicare payment rates and increasing the company&#146;s expenses associated with a <FONT STYLE="white-space:nowrap">non-deductible</FONT> health
insurance industry fee and other assessments; the company&#146;s financial position, including the company&#146;s ability to maintain the value of its goodwill; and the company&#146;s cash flows. Additionally, potential legislative changes,
including activities to repeal or replace, in whole or in part, the Health Care Reform Law, creates uncertainty for Humana&#146;s business, and when, or in what form, such legislative changes may occur cannot be predicted with certainty.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana&#146;s continued participation in the federal and state health insurance exchanges, which entail uncertainties associated with mix, volume of business and the operation of premium stabilization programs that are
subject to federal administrative action, could adversely affect the company&#146;s results of operations, financial position and cash flows. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana&#146;s business activities are subject to substantial government regulation. New laws or regulations, or changes in existing laws or regulations or their manner of application could increase the company&#146;s
cost of doing business and may adversely affect the company&#146;s business, profitability and cash flows. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company&#146;s business may be adversely affected. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana&#146;s pharmacy business is highly competitive and subjects it to regulations in addition to those the company faces with its core health benefits businesses. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in the prescription drug industry pricing benchmarks may adversely affect Humana&#146;s financial performance. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If Humana does not continue to earn and retain purchase discounts and volume rebates from pharmaceutical manufacturers at current levels, Humana&#146;s gross margins may decline. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Humana&#146;s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Downgrades in Humana&#146;s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The securities and credit markets may experience volatility and disruption, which may adversely affect Humana&#146;s business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or
results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and
uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana advises investors to
read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2017, June&nbsp;30, 2017, September&nbsp;30, 2017; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Form <FONT STYLE="white-space:nowrap">8-Ks</FONT> filed during 2017. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Humana </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc. is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health
plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military
service personnel, and communities at large. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To accomplish that, we support physicians and other health care professionals as they work to deliver the
right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools &#150; such as <FONT STYLE="white-space:nowrap">in-home</FONT> care, behavioral health, pharmacy services, data analytics and
wellness solutions &#150; combine to produce a simplified experience that makes health care easier to navigate and more effective. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g464609img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g464609img001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +@#: P$1  (1 0,1 ?_$ -H   ,! 0$! 0
M      @)"@ ' P$& 0 " P$! 0$!           '"  &"04$ P(!$   !0,"
M P('!P\)"0     ! @,$!1$&!P ((1(),1-!46$B%!47<3)T-19W.(&AL=%2
M(S.TM39VIK8W&)'!0E.S-%5U)G*R8Z-$5&2&.1$  0($ P,%"@<+" D%
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M(*]KXMS'MLREXW=-Q]OVW!M57LM*R)P2:MFR)#&.(F$Y3&5-2A"% QCF$"@
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M-\X([T38YBLFX\$Y[O*UY1LHC-V3?KF3CA4(=-%ZV;2X2\-(M^< YVKI$2"
MEK4:TJ(#I&\UTU?DC42IK[FRJ0K"H&7Q9B4O@, Z]H3ER^;U0A1'$WI]9^]#
M^+)ZP&W-]:T8[O6*OZW;G28MPEXEC;Z<PW*_(CW:Q8V01>().FBB@<Q.<A#@
M4:&"O'3EVCM+Y1I;-3FYI44)2 =FWD@S,:BV%#;9<!"^&<)0DO>EFZT]P^X.
MZLHV.QF6-MR\=;K!DG.M46DD<\7&),W"RS1LNZ(W*HL0>4!.(\H5\.E%U?S1
M09^SJG,=B!2PD ?Z8"V:KQ9[W7J<;02#%%VS8.;I_P",A#PXCG@X^0D]V^$*
M^73S:6TZJ?1H%6TVUSU3!\RJ0,NL#D]@5X(F&P%](##X>$,K6> ^[\H4?MZS
M[R>=[4"RG_JS'KF #E\SNU/Z8]8Q;-._%$U_E<C^+*:U=N'V=5?VWJB&AK_H
MROF5> 1$;BOCG''1?#[7;6']<F.LGLM>_P!9?VE3^%<+';/>9ST_'%O<@-6+
M_P""NOQ976MEQQH*SYH^ PSJ3.G=]&(793CD"1#QWT\X_P#LJFLBKLT59P<5
M_P!41ZRH5AS[>_Y@^&*FNI%B*4RWM#G4H!DYD9^QUH"_6#%H3OG+QO"-%$9A
MLDD'G*B:(=K*<H<1%,*:T&URR[5W_(C@I$E;E(EBH*1B5);0L$#\/O0P6:*)
MRX980RWYX"5? #"!=C>ZMOM2RRYNN;CG<W95T1(VW=K2+*BK(M6@.Q?,I2,1
M7.FBNLR>% 5$S& %"5 !*8-)AHOJ)1Z:9B#BVE(RK7$^U-D8I5U=TP'<IWI6
M6+DL5&"3,0W3.W5DV[/L875 8_87A==PW-;LG"-&CR%^3\<R/,1SAD9R^>OU
M!$P-/2 ,)$2*<XAR\P5KIELT]HW)-PM=18\LMJ5Q&U"<I#'#8)P1[KJ%9G;8
MM#"5*<4DB4)?V1@([M]O1:E,8,B17,)0 H";N)#F'AQ[?'QII3M&T[NH5.?E
MW9M7X0<,"'*E0*K,+;R4E(+FP]<.*ZV 4Q=A+]/I_P#9XNFV[5H_RS0?KBX+
MNIF-I:/^\'JF.6]$WXSSW\&LW_?E=5#LJ?:.8/1:]:.'IC^>7U>.'$[K/HU9
MX^:J^/V=D=-3J![GWO\ 4%>K!.S!]C._-GP1*IL'4*3>%M^#C7Y:H]GEA9/6
M<6AA=<U2LZ9?DVJ8GX=TPNN3CN9M0KG<AKG6<Q++35J8SS'&ME'+.R'$M:UP
MD00,L9I&W L@]9RBZA $$FB+QAW1A&@ 94NF5[5V7*BYVZ@OU$V7%H94A4A.
M05)4^]!1U,M]2_PJJG3,@ &75RP&'3PWQVIMB3NJQ\H,9E>Q;ED23D?)PC4K
M]Q 3Q6I6CLKR/$Y%5&LD@BD '(-4S)\0, AH1Z :O6G)5O=HKP@H1B%3YL9]
MZ*_DO-;=F*VJS"0\$=LW^]0S"^=\,/,/XP8W1,N9J;A)-[<,Q'>I(Z,1A7A)
M B"*;HYG;]RZ%/EX%(1, K41H&K7K5KGE'/.4AES+3:U(FDDD2  Y)"<>[-6
M?K5>;>IAELXQR/H_GY]U;\3" B;&-TB(@42E$#/XBE"B(B7@/CU5>RNVBFSK
M4EK8EI/JB.-I&6_K*H6@204F'8Y W9M[0ODMH1EHK3PH7 I:R#A26.P/,W.R
M!EZTA(A)..=D%9FG*(%*LY.BW56/R 8H )].??=1FK;<Q0O(FGB2$N>"Y578
MTSH2F1)<EMZXZ;_$IC+_ +Y3]V/M<_ *_FS_ %'X+XW_ /']]Y-=O]^*+]&K
M\UO=SFCW_6YZ?,G][K[T+NZCF/\ :-=F5K*>[A\]7'BRZF]E>C0T+"V/=-S-
MY"%":=J$DEGD#:\XU;J"Z%5/NS*%/V#RTH(@'7BVZ8569*1>=KB[37@,*X24
MMU*@48S)X++B9[=J@>B*#G.GRRZ^C]XGU-N\FZ'#U>8A4$_T[+9V_6OAR;C]
MOF1YG)EKC>;Y>8GYJ!G;><%FE&S409),)V#@G!4F[4"!SD3.0PU'FK4 (FA%
M)DRCRLIO)=6NKH..H[ZDO(QD)B3S;:L.>4H[^3V[.W:U)M#BG*7B[2% SD,/
M*2#WH8 L!12,'-R@(E\ZE:#4/!X=&DAHM."<D;IWCS88]Z+DG;T2A%._W'.R
M>Y]P#R4S?N%NG&F01M2WF[NV8FQ+QN)F$:D1T,8_"1A[0F6 *.43"!DRKB)>
M7B ".DWUPM&E57FL.9RNJZ6^>R2"4M5:D\'RL?R+#B)[?C3Z(#V=&,HN74*O
M#[C==R !TC^B@COPPW8K XBMS;K:L3A:^9+(>/$)*X#Q5TRD)*P#UZZ6EESR
M"1XR6C8I^B#1Z)B )T"@>@"%0H.COI2QEUG+%(C++RGK&/S2B'!O'"<^(A"N
M;S@((&5TV]%"!9E%=-SF?,/E!)@=]_<%L!GG\"RW+WJ6R<A&CS_)Z8MF/NF1
MO)*.'O>Z];-;4MVX5UH4IN?NRODB)CQY#=NJ5K52:353RAGNJ%-5[HGN)=4K
MED3P6G(X.:6LI+;E>G$H7/#!1/\ 123+[IPH)U@WIY*.C':[W[C;L#&JB@O@
MO)2ZY"U]Z5=2TT^8:=@\FE=?L&@A5--]4*.6 4Q7?_EVP-ZBDR27DE540C=P
M\EW9_P ..KV9B[I)Q @>\=R^0[P4 R7,F2QLKV^T$0_KBL\:JFY##XU ]W78
MMMB[-HI)/7NI+,\2AFO'@I">]'OME+ID%>74J*_1>_\ :A]&*&F&/X<[?:8A
ME#AAD;(D4;6E2HS*AR6X9K(%7> A+,D9@ZJ0&5-RJHE4$2TY>P!=>PLY91I[
MPLLNJ7EGV-0"UAS>X6[B9+0ER<OYD^B"W:TVQ-K;3:5%5'[.0DG>_-RQ/E &
M?6)]$(IQ)B3IQ,,N6"_M[=;>\[<S2^X%S P:N,L@,$)6>3E4SQT:N]<6$D@U
M0</!*05#*$(4 J8P!QTF&6++H?\ O;0NT%X>]O37-FG06JT[SP4=T$FF"9$S
M'E$##$P*+939$37M&@J'5/ C<!#V)GR[S8&V*490B1XU^1RMW*1F3LKM4I#&
M%-N9 X+'*4I3B)B%&H4 1&G8.GUJFFS0/)>= $E[YW3A@-^0V[)2E/H@SU0*
MJ<\7R1N*GZ,L=D34V/B/IM-\K6E(0.Z^^9"=;Y!A7D/;ZV,<A(I2$TG<3=9A
M$*2*UA(HH)N'X$1%8YRD* \PF .((C;++H0G-="NVWA]5T%6T:=):K9*=!5P
MPHJI@F1\J>\0.<B Y04F1A>%J;JG#6[V(W7I?W<N_%+KP$A:.N<1*GW"W>]M
M03[H_>4H \03K3AVZ?6XI"J)\)4$I*#ODS,A+D^].#,-W@KW/,EC$PTEA[IH
M*WB_<&W<WVV?*72Y<&CQQ;D-4J$@:9.H=AZ1[/C$4(D['N^\YN4P!6M..D*J
M;)H2O,2G7KR\BK]L3-'"KC^6F9"8I=V1,^673 2>I<A_6^\FI=X_$V;KWG<O
M]7+Q=,4X$*R"-0*JH0[(&J0&44*($% $"@!E04* =V*/$_,'+2O-PKI\F&TA
MO_$.()#:9S3Y)3+XT\)2VS@XL\+V-(PX.YA/Y,NF)V]RN/>EO=-^7(O!Y]<X
MON_UH\]?-;-LF_+LM+UD!N5[Z$E%V>[@R5<@83^B/#D[P34 !J&DBU L^A#^
M8ZYY5V#%R4H\9M+54IA*IF>X44ZFOP%J@)9CI<CKK%%ZI<0_/$!+I]5LCOQY
M[>\==+:W))=*7W"2&1KT=1<PC$O+IL6^[7@8P%8YT19TT82%GHQ+J7;(B<Z'
M?.#+&.%")F,(:\N4[1V>4TCFY=0JM*3/\E5X?#3CO1];;3:>)9,J@J7TI=E.
M72W&VS8IZ?<3GW$\EC7='>-U7TQN]FXL^W7N-;[C&<U*%([!O'NW\E9#!HT(
MH4QQ%159( Y>(A4-?;(%FT4;S:TY9;PZY>16(+:"S6!)<DK<$UTZ42(WMJ@G
MG,?FW4V4A?$*HZB=7,;H"7-T\WQ-W'KAAO4EM+;Y=EDXU;;C<K3.*X5G=4DO
M;<C!VQ.W*I+RBL.4CQDLA 04^NT(V;!S@=4B935H!A$*:.>NM!D^KL%*C/-<
M:6G%22A2&WE35+RA)EMP[92F (O&<VK6Y;&TWATMM\48@*/Q3AY*28_(=-:R
M]J]HKY4_AUS)<.5WKT+=&Z/7=IW+;!(=ND#P(XC8)ZW(%-V+I05!,*8J"6@
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4,?-Y]GW<T=;=M_RE>9_.\WX(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
